Ovid Therapeutics Inc. (OVID)
Nasdaq: OVID · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2015
Who owns Ovid Therapeutics Inc.
As filed with the SECHolders of 5% or more
7
Takeda Pharmaceutical Company Limited holds 12.3% of Common Stock, par value $0.001 per share, as its SCHEDULE 13G/A filed Dec 9, 2025 says.
Directors and officers
10
report now, of 20 people on the record since 2017. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 7 named at left.
Holders of 5% or moreshare of the class, as filed
Takeda Pharmaceutical Company Limited
SCHEDULE 13G/A · filed Dec 9, 2025 · Common Stock, par value $0.001 per share
Janus Henderson Group PLC
SCHEDULE 13G · filed Dec 8, 2025 · Common Stock
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock par value $0.001 per share · 9.9% in Dec 18, 2025
Sirenia Capital Management LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, par value $0.001 per share
Affinity Asset Advisors, LLC
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, par value $0.001 per share · 9.1% in May 14, 2026
Eventide Asset Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · 7.3% in May 15, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock · 1.9% in Jul 17, 2025
ADAR1 Capital Management, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 6.9% in Feb 17, 2026
Balyasny Asset Management L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · reported falling below 5%, from 5.33% in May 15, 2026
Jeremy M. Levin
SCHEDULE 13G/A · filed May 14, 2026 · COMMON STOCK, $0.001 PAR VALUE · reported falling below 5%
Federated Hermes, Inc.
SCHEDULE 13G/A · filed Jul 8, 2026 · COMMON STOCK · reported falling below 5%, from 5.94% in Jan 8, 2026
Madison Avenue Partners, LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, par value $0.001 per share (the "Common Stock") · reported falling below 5%
Point72 Asset Management, L.P.
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share · reported falling below 5%, from 5.1% in Jan 5, 2026
Rubric Capital Management LP
SCHEDULE 13G/A · filed Jul 9, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
Biotechnology Value Fund L P
SCHEDULE 13G/A · filed Jul 21, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%
What OVID reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Takeda Pharmaceutical Company Limited
An entity · legal entity · owns, named in the 10-K filed Mar 18, 2026
Gensaic, Inc
An investee · investee · invested in, named in the 10-K filed Mar 18, 2026
Graviton Bioscience Corporation
An investee · investee · invested in, named in the 10-K filed Mar 18, 2026
Marinus Pharmaceuticals, Inc.
An investee · investee, legal entity · invested in, named in the 10-K filed Mar 18, 2026
Insider tradesForm 4
2sales
0purchases
0sales on a scheduled plan
2people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 23 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Alexander Margaret A. | President and CEO | 1 | $0 | 0 | 0 | $0 |
| Rona Jeffrey A | CBFO | 1 | $0 | 0 | 0 | $0 |